August 11, 2026

Listing Department **Code:** ***532321***
BSE LIMITED
P J Towers, Dalal Street,
Mumbai–400 001

Listing Department **Code:** ***ZYDUSLIFE***
NATIONAL STOCK EXCHANGE OF INDIA LIMITED
Exchange Plaza, C/1, Block G,
Bandra Kurla Complex,
Bandra (E),
Mumbai–400 051

Re: **Outcome of Board Meeting**

Ref.: Disclosures under regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("the Listing Regulations")

Dear Sir / Madam,

The Board of Directors ("the **Board**") at their meeting held today i.e. August 11, 2026, based on the recommendations of Audit Committee, approved the unaudited financial results for the quarter ended on June 30, 2026.

In this regard, please find enclosed the following:

1. the unaudited financial results (standalone and consolidated) for the quarter ended on June 30, 2026, reviewed by the Audit Committee and taken on record by the Board pursuant to regulation 33 of the Listing Regulations.

2. the limited review reports of Deloitte Haskins & Sells LLP, Chartered Accountants and the Statutory Auditors of the Company ("**Deloitte**") certifying the limited review of the unaudited financial results (standalone and consolidated) of the Company for the quarter ended on June 30, 2026, pursuant to regulation 33 of the Listing Regulations.

The Trading Window under SEBI (Prohibition of Insider Trading) Regulations, 2015 shall remain closed for trading till Thursday, August 13, 2026, and shall reopen on and from Friday, August 14, 2026, for the Directors and Designated Persons of the Company.

The financial results and limited review reports will be available on the website of the Company at www.zyduslife.com.

The Board meeting commenced at 12:00 noon and concluded at 1:15 p.m.

Please receive the information and disclosures in order.

Thanking you,

Yours faithfully,
For, **ZYDUS LIFESCIENCES LIMITED**

DHAVAL NARENDRA SONI
Digitally signed by DHAVAL NARENDRA SONI
Date: 2026.08.11 13:20:18 +05'30'

DHAVAL N. SONI
COMPANY SECRETARY AND COMPLIANCE OFFICER
MEMBERSHIP NO. FCS7063

Encl.: As above

Deloitte Haskins & Sells LLP

Chartered Accountants
19th Floor, Shapath-V
S.G. Highway
Ahmedabad - 380 015
Gujarat, India

Tel: +91 79 6682 7300
Fax: +91 79 6682 7400

INDEPENDENT AUDITOR'S REVIEW REPORT ON THE INTERIM STANDALONE FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF
ZYDUS LIFESCIENCES LIMITED

1. We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of **ZYDUS LIFESCIENCES LIMITED** ("the Company"), for the quarter ended June 30, 2026 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").

2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Deloitte Haskins & Sells LLP
Chartered Accountants
(Firm's Registration No. 117366W/W-100018)

DELOITTE HASKINS & SELLS LLP * AHMEDABAD * CHARTERED ACCOUNTANTS *

Kartikeya Raval

Kartikeya Raval
Partner
(Membership No. 106189)
UDIN: 26106189ZDQKSQ7439

Place: Ahmedabad
Date: August 11, 2026

Zydus Lifesciences Limited

Registered Office: Zydus Corporate Park, Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar),
Near Vaishnodevi Circle, Sarkhej- Gandhinagar Highway, Ahmedabad - 382481
Tel. No.: (+91-79) 4804 0000 Website: www.zyduslife.com
CIN : L24230GJ1995PLC025878

Statement of Standalone Unaudited Financial Results for the Quarter Ended June 30, 2026

Sr. No.		Particulars	INR Million			
			Quarter ended			Year ended
			30/06/2026	31/03/2026	30/06/2025	31/03/2026
			(Unaudited)	(Unaudited) (Refer Note-9)	(Unaudited)	(Audited)
1		**Income**				
	a	Revenue from operations				
	i	Sale of products	27,235	35,646	24,958	110,764
	ii	Other operating revenues	1,487	1,763	925	4,076
	iii	Total revenue from operations	28,722	37,409	25,883	114,840
	b	Other income (Refer Note-3)	1,237	4,951	1,571	16,675
	c	**Total income**	29,959	42,360	27,454	131,515
2		**Expenses**				
	a	Cost of materials consumed	8,615	9,367	8,537	35,307
	b	Purchases of stock-in-trade	1,982	689	561	1,977
	c	Changes in inventories of work-in-progress, finished goods and stock-in-trade	(2,167)	(562)	(60)	(1,516)
	d	Employee benefits expense	5,614	5,139	4,872	19,662
	e	Finance costs	1,031	1,155	1,376	4,829
	f	Depreciation and amortisation expense	1,519	1,509	1,300	5,612
	g	Other expenses	9,203	9,364	6,481	32,443
	h	Net (gain) on foreign currency transactions	(395)	(6,479)	(362)	(12,287)
	i	**Total expenses**	25,402	20,182	22,705	86,027
3		**Profit before exceptional items and tax (1-2)**	4,557	22,178	4,749	45,488
4		Exceptional item (Refer Note-4)	-	1,068	-	1,669
5		**Profit before tax (3-4)**	4,557	21,110	4,749	43,819
6		Tax expenses (Refer Note-5)				
	a	Current tax	1,177	4,467	896	8,998
	b	Deferred tax	(16)	(577)	6	(777)
	c	Total tax expenses	1,161	3,890	902	8,221
7		**Net Profit for the period/ year (5-6)**	3,396	17,220	3,847	35,598
8		**Other Comprehensive Income (OCI)**				
	a	Items that will not be reclassified to profit or loss	213	18	(2)	408
	b	Income tax effect on above items	(3)	(144)	12	(121)
		Total Other Comprehensive Income	210	(126)	10	287
9		**Total Comprehensive Income (7+8)**	3,606	17,094	3,857	35,885
10		Paid-up equity share capital (Face value Re. 1/-) (Refer Note-6)	998	1,006	1,006	1,006
11		Other equity				235,711
12		**Earnings per share (not annualised for the quarter)**				
	a	Basic (INR)	3.38	17.11	3.82	35.38
	b	Diluted (INR)	3.38	17.11	3.82	35.38

Notes :

[1] The above financial results were reviewed and recommended by the Audit Committee and then approved by the Board of Directors at their meetings held on August 11, 2026.

[2] These financial results have been prepared in accordance with the Companies [Indian Accounting Standards] Rules, 2015 [Ind AS] as amended, prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and in terms of Regulation 33 of Securities and Exchange Board of India [Listing Obligations and Disclosure Requirements] Regulations, 2015, as amended.

[3] Other income includes dividend from subsidiaries and joint ventures, of INR 3,333 Million for the quarter ended March 31, 2026 and INR 11,033 Million for the year ended March 31, 2026.

[4] Exceptional items comprise:

Sr. No.	Particulars	INR Million			
		Quarter ended			Year ended
		30/06/2026	31/03/2026	30/06/2025	31/03/2026
		(Unaudited)	(Unaudited) (Refer Note-9)	(Unaudited)	(Audited)
a	Impairment in the value of investment in the shares of Zydus VTEC Limited, a wholly owned subsidiary	-	1,068	-	1,068
b	One time impact of New Labour Codes [Refer Note-7]	-	-	-	601
c	**Total**	-	1,068	-	1,669

[5] For the financial year ended March 31, 2026, the Company had computed the provision for income tax as per the option permitted under section 115BAA of the Income Tax Act, 1961. Accordingly, the Company had recognised provision for income tax for the year ended March 31, 2026 and re-measured its deferred tax assets and liabilities basis the rate prescribed under the said section. The gain on such remeasurement of INR 515 Million was provided in the quarter ended March 31, 2026. Hence, the tax expense for the quarter ended June 30, 2026 is not comparable with other reported periods.

For Identification Purposes Only
DELOITTE HASKINS & SELLS LLP
MUMBAI
CHARTERED ACCOUNTANTS
For Identification Purposes Only

[6] The Board of Directors at their meeting held on May 19, 2026, approved the proposal for buyback of equity shares, on proportionate basis, through tender offer route, amounting to INR 11,000 Million at a price not exceeding INR 1,150 per share [Buyback Price]. Subsequently, as per Regulation 5 [via] of the SEBI [Buy-back of Securities] Regulations, 2018, the Buyback Committee, at its meeting held on May 27, 2026 has approved increase in buyback price from INR 1,150 per share to INR 1,260 per share. Pursuant to buyback, the Company has extinguished 8,730,158 equity shares [representing 0.87% of the total number of equity shares of the Company] on June 18, 2026, in compliance with the applicable rules and regulations. Consequently, the paid up equity share capital has been reduced by INR 8 Million. The aggregate amount paid for the buy back is INR 11,063 Million, including related expenses.

[7] Effective November 21, 2025, the Government of India has consolidated 29 existing labour legislations into a unified framework comprising four Labour Codes collectively referred to as the "New Labour Codes". The Company has assessed the financial implications of these changes, which had resulted in one time increase in gratuity and leave encashment liability mainly on account of past service cost by INR 601 Million. Such increase was primarily arising due to change in the definition of "wages" for employees and contract labours. The Company continues to monitor the developments pertaining to the New Labour Codes and the impact, if any, will be accounted in accordance with applicable accounting standards.

[8] The Company has one segment of activity viz., "Pharmaceuticals".

[9] The figures of the quarter ended March 31, 2026 are balancing figures between audited figures in respect of the full financial year and year to date figures upto the third quarter of the said financial year.

[10] Figures of previous reporting periods have been regrouped/ reclassified wherever necessary to correspond with the figures of the current reporting period.

By Order of the Board,
For Zydus Lifesciences Limited,

For Identification Purposes Only
DELOITTE HASKINS & SELLS LLP
MUMBAI
CHARTERED ACCOUNTANTS
For Identification Purposes Only

Ahmedabad, August 11, 2026

Dr. Sharvil P. Patel
Managing Director
DIN: 00131995

Deloitte Haskins & Sells LLP

Chartered Accountants
19th Floor, Shapath-V
S.G. Highway
Ahmedabad - 380 015
Gujarat, India

Tel: +91 79 6682 7300
Fax: +91 79 6682 7400

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM CONSOLIDATED FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF ZYDUS LIFESCIENCES LIMITED

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of **ZYDUS LIFESCIENCES LIMITED** ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), and its share of the net profit after tax and total comprehensive income of its joint ventures for the quarter ended June 30, 2026 ("the Statement") being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").

2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of Parent's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

   We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of the entities listed in the Annexure to this report.

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

DELOITTE HASKINS & SELLS LLP * AHMEDABAD * CHARTERED ACCOUNTANTS

Regd. Office: One International Center, Tower 3, 31st floor, Senapati Bapat Marg, Elphinstone Road (West), Mumbai-400 013, Maharashtra, India.
Deloitte Haskins & Sells LLP is registered with Limited Liability having LLP identification No: AAB-8737

6. We did not review the interim financial information of 53 subsidiaries included in the consolidated unaudited financial results, whose interim financial information reflect total revenues of Rs 62,106 Million for the quarter ended June 30, 2026, total net loss after tax of Rs 738 Million for the quarter ended June 30, 2026 and total comprehensive loss of Rs 740 Million for the quarter ended June 30, 2026, as considered in the Statement. These interim financial information have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

   Our conclusion on the Statement is not modified in respect of these matters.

7. The consolidated unaudited financial results includes the interim financial information of 42 subsidiaries which have not been reviewed by their auditors, whose interim financial information reflect total revenue of Rs 4,256 Million for the quarter ended June 30, 2026, total loss after tax of Rs 920 Million for the quarter ended June 30, 2026 and total comprehensive loss of Rs 893 Million for the quarter ended June 30, 2026, as considered in the Statement. The consolidated unaudited financial results also includes the Group's share of profit after tax of Rs 378 Million for the quarter ended June 30, 2026 and total comprehensive income of Rs 378 Million for the quarter ended June 30, 2026, as considered in the Statement, in respect of 4 joint ventures, based on their interim financial information which have not been reviewed by their auditors. According to the information and explanations given to us by the Management, these interim financial information are not material to the Group.

   Our Conclusion on the Statement is not modified in respect of our reliance on the interim financial information certified by the Management.

For Deloitte Haskins & Sells LLP
Chartered Accountants
(Firm's Registration No. 117366W/W-100018)

DELOITTE HASKINS & SELLS LLP
AHMEDABAD
CHARTERED ACCOUNTANTS

Kartikeya Raval

Kartikeya Raval
Partner
(Membership No. 106189)
UDIN: 26106189KRWWZN3848

Place: Ahmedabad
Date: August 11, 2026

ANNEXURE TO THE INDEPENDENT AUDITOR'S REPORT:

The Parent

1. Zydus Lifesciences Limited

List of Subsidiaries

1. Sentynl Therapeutics Inc
2. Zydus Animal Health and Investments Limited
3. Zydus Healthcare (USA) LLC
4. Zydus Healthcare Limited
5. Zydus Healthcare Philippines Inc.
6. Zydus International Private Limited
7. Zydus (Lanka) Private Limited
8. Zydus Pharmaceuticals (USA) Inc.
9. Zydus Wellness Limited
10. Zydus Worldwide DMCC
11. Dialforhealth Greencross Limited
12. Dialforhealth Unity Limited
13. Zydus Pharmaceuticals Limited
14. Zydus Strategic Investments Limited
15. Zydus VTEC Limited
16. Zynext Ventures PTE. LTD.
17. Zydus Pharmaceuticals UK Limited
18. Zydus Pharmaceuticals Canada Inc.
19. Zydus Lifesciences Global FZE
20. Viona Pharmaceuticals Inc., USA
21. Violio Healthcare Limited
22. Biochem Pharmaceutical Private Limited
23. Zydus Medtech Private Limited
24. Zydus MedTech (France) SAS
25. German Remedies Pharmaceuticals Private Limited
26. M/s. Recon Pharmaceuticals and Investments
27. Zydus Pharmaceuticals Mexico SA De CV
28. Zydus Pharmaceuticals Mexico Services Company SA De C.V.
29. ZyVet Animal Health Inc [USA]
30. Liva Nutritions Limited
31. Zydus Wellness Products Limited
32. Zydus Wellness International DMCC
33. Zydus Wellness BD Private Limited
34. Naturell (India) Private Limited (Under liquidation)
35. Naturell Inc. (USA)
36. Alidac Healthcare Myanmar Limited
37. Etna Biotech S.R.L. (Under liquidation)
38. Zydus France SAS
39. Zydus Healthcare S.A. (Pty) Ltd.
40. Zydus Netherland B.V
41. Zydus Therapeutics Inc.
42. Script Management Services (Pty) Ltd.
43. Alidac Pharmaceuticals SA (Pty) Ltd.
44. Laboratorios Combix S.L.
45. Zydus Nikkho Farmaceutica Ltda.
46. Zynext Ventures USA LLC, USA
47. LiqMeds Worldwide Limited

DELOITTE HASKINS & SELLS LLP * AHMEDABAD * CHARTERED ACCOUNTANTS *

48. LiqMeds Limited
49. Medsolutions (Europe) Limited
50. LiqMeds Lifecare Limited
51. LM Manufacturing Limited
52. LM Manufacturing India Private Limited
53. Amplitude Surgical SAS [France]
54. Amplitude Orthopedics Corporation [USA]
55. Amplitude Australia Pty Ltd [Australia]
56. Amplitude South Africa Pty Ltd [South Africa]
57. Amplitude Latin America SA [Brazil]
58. Amplitude SAS [France]
59. SCI Les Tilleuls [France]
60. SCI SOFAB FALLA [France]
61. Amplitude Ile de France [France]
62. Duotech Amplitude SAS [France]
63. Amplitude Sud SAS [France]
64. Amplitude Nord SAS [France]
65. Amplitude New Zealand Limited [New Zealand]
66. Ortho Santé (Amplitude Ouest) [France]
67. Amplitude Benelux [Belgium]
68. Amplitude Suisse SA [Switzerland]
69. Amplitude GmbH [Germany]
70. Mediconseil [France]
71. Alidac UK Limited [UK]
72. Comfort Click UK [UK]
73. Comfort Click Limited [Ireland]
74. Comfort Click LLC [USA]
75. Comfort Click Softech Private Limited
76. Zylidac Bio LLC [USA]
77. FBC Medical [France] (w.e.f April 30, 2026)
78. Aptitude Orthopedie [France] (w.e.f April 30, 2026)
79. Zydus Wellness (EU) Limited [Ireland] (w.e.f June 23, 2026)
80. Zydus Wellness Trading LLC [Dubai] (w.e.f June 24, 2026)
81. Zydus Wellness General Trading DWC-LLC [Dubai] (w.e.f June 30, 2026)
82. Zara Merger SUB Inc. [USA] (w.e.f. April 24, 2026 till June 16, 2026)
83. Assertio Holdings Inc. [USA] (w.e.f June 16, 2026)
84. Zyla Life Sciences Limited [USA] (w.e.f June 16, 2026)
85. Zyla Life Sciences US LLC [USA] (w.e.f June 16, 2026)
86. Assertio Specialty Pharmaceuticals LLC [USA] (w.e.f June 16, 2026)
87. Asio Holdings LLC [USA] (w.e.f June 16, 2026)
88. Depo DR Sub LLC [USA] (w.e.f June 16, 2026)
89. Spectrum Pharmaceuticals Inc. [USA] (w.e.f June 16, 2026)
90. Spectrum Pharmaceuticals International Holdings LLC [USA] (w.e.f June 16, 2026)
91. Allos Therapeutics Inc. [USA] (w.e.f June 16, 2026)
92. Talon Therapeutics Inc. [USA] (w.e.f June 16, 2026)
93. Assertio Distribution LLC [USA] (w.e.f June 16, 2026)
94. Assertio Management LLC [USA] (w.e.f June 16, 2026)
95. Alligator IP LLC [USA] (w.e.f June 16, 2026)
96. Spectrum Oncology Private Limited (w.e.f June 16, 2026) (under liquidation)

DELOITTE HASKINS & SELLS LLP
AHMEDABAD
CHARTERED ACCOUNTANTS

List of Joint Ventures

1. Zydus Hospira Oncology Private Limited
2. Zydus Takeda Healthcare Private Limited
3. Oncosol Limited
4. Sterling Biotech Limited

DELOITTE HASKINS & SELLS LLP * AHMEDABAD * CHARTERED ACCOUNTANTS *

Zydus Lifesciences Limited

Registered Office: Zydus Corporate Park, Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar),
Near Vaishnodevi Circle, Sarkhej- Gandhinagar Highway, Ahmedabad - 382481
Tel. No.: (+91-79) 4804 0000 Website: www.zyduslife.com
CIN : L24230GJ1995PLC025878

Statement of Consolidated Unaudited Financial Results for the Quarter Ended June 30, 2026

		INR Million			
		Quarter ended			Year ended
		30/06/2026	31/03/2026	30/06/2025	31/03/2026
Sr. No.	**Particulars**	(Unaudited)	(Unaudited) (Refer Note-16)	(Unaudited)	(Audited)
1	**Income**				
a	Revenue from operations				
i	Sale of products	78,020	74,344	64,670	267,197
ii	Other operating revenues	2,150	1,526	1,067	4,287
iii	Total revenue from operations	80,170	75,870	65,737	271,484
b	Other income	1,061	1,342	1,549	5,095
c	**Total income**	81,231	77,212	67,286	276,579
2	**Expenses**				
a	Cost of materials consumed	12,512	13,472	12,189	51,096
b	Purchases of stock-in-trade	12,892	9,717	6,582	30,705
c	Changes in inventories of work-in-progress, finished goods and stock-in-trade	(3,006)	(3,426)	(876)	(8,875)
d	Employee benefits expense	13,682	12,388	10,052	44,179
e	Finance costs	1,560	1,230	847	4,389
f	Depreciation and amortisation expense	5,547	5,084	2,381	14,080
g	Other expenses	25,365	24,624	17,476	82,433
h	Net (gain) on foreign currency transactions	(569)	(6,449)	(571)	(12,805)
i	**Total expenses**	67,983	56,640	48,080	205,202
3	**Profit before exceptional items, tax and share of profit/ [loss] of joint ventures (1-2)**	13,248	20,572	19,206	71,377
4	Exceptional items (Refer Note-4)	182	3,975	-	5,166
5	**Profit before tax and share of profit/ [loss] of joint ventures (3-4)**	13,066	16,597	19,206	66,211
6	Tax expenses (Refer Note-5)				
a	Current tax	3,759	5,256	2,307	13,795
b	Deferred tax	(217)	(2,072)	2,033	2,152
c	Total tax expenses	3,542	3,184	4,340	15,947
7	**Profit before share of profit/ [loss] of joint ventures (5-6)**	9,524	13,413	14,866	50,264
8	Share of profit/ (loss) of joint ventures (net of tax)	378	(3)	344	971
9	**Net profit before non-controlling interests (7+8)**	9,902	13,410	15,210	51,235
10	Non-controlling interests	504	685	542	835
11	**Net profit for the period/ year (9-10)**	9,398	12,725	14,668	50,400
12	**Other Comprehensive Income (OCI)**				
a i	Items that will not be reclassified to profit or loss	263	(694)	(31)	(329)
a ii	Income tax effect on above items	(8)	(165)	17	(135)
b i	Items that will be reclassified to profit or loss	(580)	(3,989)	88	(7,298)
b ii	Income tax effect on above items	-	-	-	-
c	Share of OCI of joint ventures (net of tax)	-	14	(25)	14
d	Total Other Comprehensive Income before non-controlling interests	(325)	(4,834)	49	(7,748)
e	Non-controlling interests	(47)	(11)	-	(21)
f	**Total Other Comprehensive Income**	(278)	(4,823)	49	(7,727)
13	**Total Comprehensive Income (9+12 d)**	9,577	8,576	15,259	43,487
14	**Total Comprehensive Income attributable to:**				
	Owners of the Company	9,120	7,902	14,717	42,673
	Non-controlling interests	457	674	542	814
15	Paid-up equity share capital (Face value Re. 1/-) (Refer Note-15)	998	1,006	1,006	1,006
16	Other equity				270,108
17	**Earnings per share (not annualised for the quarter)**				
i	Basic (INR)	9.35	12.65	14.58	50.09
ii	Diluted (INR)	9.35	12.65	14.58	50.09

For Identification Purposes Only
DELOITTE HASKINS & SELLS LLP
CHARTERED ACCOUNTANTS
MUMBAI
For Identification Purposes Only

Segment Information:

Sr. No.		Particulars	INR Million			
			Quarter ended			Year ended
			30/06/2026	31/03/2026	30/06/2025	31/03/2026
			(Unaudited)	(Unaudited) (Refer Note-16)	(Unaudited)	(Audited)
1		**Segment revenue:**				
	a	Pharmaceuticals	62,981	57,761	57,142	224,121
	b	Consumer products	14,359	14,834	8,575	39,540
	c	Medical technologies	2,830	3,275	20	7,823
	d	**Total revenue from operations**	80,170	75,870	65,737	271,484
2		**Segment results:**				
	a	Pharmaceuticals	12,452	19,396	18,513	70,488
	b	Consumer products	1,613	1,764	1,434	2,671
	c	Medical technologies	(817)	(588)	(741)	(1,782)
	d	**Total profit before tax before exceptional items**	13,248	20,572	19,206	71,377
3		**Segment assets:**				
	a	Pharmaceuticals	390,479	357,983	314,735	357,983
	b	Consumer products	104,575	103,062	63,968	103,062
	c	Medical technologies	62,409	63,021	2,619	63,021
	d	**Total assets**	557,463	524,066	381,322	524,066
4		**Segment liabilities:**				
	a	Pharmaceuticals	154,114	119,684	94,384	119,684
	b	Consumer products	45,200	44,790	6,001	44,790
	c	Medical technologies	63,860	63,770	2,095	63,770
	d	**Total liabilities**	263,174	228,244	102,480	228,244

Notes :

[1] The above consolidated financial results, relate to Zydus Lifesciences Limited [the Parent], its Subsidiaries [together referred as the Group] and Joint Ventures, are prepared by applying Ind AS 110 "Consolidated Financial Statements" and Ind AS 28 "Investments in Associates and Joint Ventures".

[2] The above financial results were reviewed and recommended by the Audit Committee and then approved by the Board of Directors at their meetings held on August 11, 2026.

[3] These financial results have been prepared in accordance with the Companies [Indian Accounting Standards] Rules, 2015 [Ind AS] as amended, prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and in terms of Regulation 33 of Securities and Exchange Board of India [Listing Obligations and Disclosure Requirements] Regulations, 2015, as amended.

[4] Exceptional items comprise:

Sr. No.	Particulars	INR Million			
		Quarter ended			Year ended
		30/06/2026	31/03/2026	30/06/2025	31/03/2026
		(Unaudited)	(Unaudited) (Refer Note-16)	(Unaudited)	(Audited)
a	Provision for severance compensation due to rightsizing of operations at Assertio Holdings, Inc.	1,091	-	-	-
b	Provision for amount payable pursuant to settlement of class action antitrust lawsuits by Zydus Pharmaceuticals Inc. [Refer Note-13]	559	-	-	-
c	Receipt of amount pursuant to settlement of a litigation related to an Asset Purchase Agreement entered into by Zydus Worldwide DMCC with Teva Pharmaceutical Industries Ltd. [Refer Note-14]	(1,468)	-	-	-
d	One time settlement payment [Refer Note-6]	-	3,975	-	3,975
e	One time impact of New Labour Codes [Refer Note-7]	-	-	-	849
f	Expenses related to acquisition of Comfort Click Limited [Refer Note-9]	-	-	-	245
g	Expenses related to liquidation of Naturell (India) Private Limited, a subsidiary on a going concern basis [Refer Note-10]	-	-	-	97
h	**Total**	182	3,975	-	5,166

[5] a For the financial year ended March 31, 2026, the Parent had computed the provision for income tax as per the option permitted under section 115BAA of the Income Tax Act, 1961. Accordingly, the Parent had recognised provision for income tax for the year ended March 31, 2026 and re-measured its deferred tax assets and liabilities basis the rate prescribed under the said section. The gain on such remeasurement of INR 515 Million was provided in the quarter ended March 31, 2026. Hence, the tax expenses for the quarter ended June 30, 2026 is not comparable with other reported periods.

b Deferred tax expense for the quarter ended June 30, 2026, quarter ended March 31, 2026, quarter ended June 30, 2025 and year ended March 31, 2026 includes net reversal of Minimum Alternate Tax [MAT] credit entitlement amounting to INR Nil, INR 218 Million, INR 146 and INR 354 Million respectively by one of the subsidiaries of the Group.

Deferred tax expense for the year ended March 31, 2026 includes recognition of MAT credit entitlement amounting to INR 191 Million by one of the subsidiaries of the Group.

[6] On February 10, 2026, Zydus Pharmaceuticals USA, Inc. [ZPUI], a wholly owned subsidiary, and the Parent entered into a Settlement and License Agreement with Astellas Pharma Inc. [Astellas] in relation to Astellas' Myrbetriq® [generic name: Mirabegron] and agreed to pay INR 10,600 Million [USD 120 Million]. Accordingly, ZPUI had paid INR 3,975 Million [USD 45 Million] towards one time settlement cost and INR 6,625 Million [USD 75 Million] towards prepaid licensing fees, which had been capitalised.

For Identification Purposes Only
DELOITTE HASKINS & SELLS LLP
MUMBAI
CHARTERED ACCOUNTANTS

[7] Effective November 21, 2025, the Government of India has consolidated 29 existing labour legislations into a unified framework comprising four Labour Codes collectively referred to as the "New Labour Codes". The Group has assessed the financial implications of these changes, which had resulted in one time increase in gratuity and leave encashment liability mainly on account of past service cost by INR 849 Million. Such increase was primarily arising due to change in the definition of "wages" for employees and contract labours. The Group continues to monitor the developments pertaining to the New Labour Codes and the impact, if any, will be accounted in accordance with applicable accounting standards.

[8] Pursuant to the acquisition of 85.6% of share capital of Amplitude Surgical SA, France [Amplitude] by Zydus MedTech (France) SAS [ZMF] on July 29, 2025 from PAI Partners and certain other shareholders through share purchase agreements and pursuant to acquisition of balance share capital of Amplitude by ZMF from remaining shareholders by October 24, 2025 through a simplified mandatory tender offer and subsequent squeeze-out, Amplitude became wholly owned subsidiary of ZMF. The cost of acquisition was EUR 300 Million. The results include the operations of Amplitude effective from July 29, 2025, with provisional purchase price allocation [PPA] figures. The PPA figures will be finalized within the measurement period, as provided by Ind AS 103.

[9] Pursuant to the Share Purchase Agreement [SPA] entered into by Alidac UK Limited [Alidac], a wholly owned subsidiary of Zydus Wellness Limited [ZWL], on August 29, 2025, to acquire Comfort Click Limited [CCL], Alidac had successfully completed the acquisition of CCL on August 29, 2025. Alidac acquired 100% outstanding ordinary shares of Class A and Class B, 71.43% of non-controlling ordinary shares of Class C and 66.67% of non-controlling ordinary shares of Class D of CCL. The cost of acquisition was GBP 239 Million alongwith a profit ticker payment of GBP 2.64 million, in accordance with the terms of SPA. The results include the operations of CCL effective from August 29, 2025, with provisional PPA figures. The PPA figures will be finalized within the measurement period, as provided by Ind AS 103.

[10] Pursuant to the voluntary liquidation process, as approved in extra ordinary general meeting of Naturell (India) Private Limited [NIPL] on July 1, 2025, effective from September 20, 2025, the Liquidator of NIPL has distributed the Business Undertaking of NIPL on a going concern basis to ZWL.

[11] Zylidac Bio LLC [Zylidac], USA, a wholly owned subsidiary, had entered into Definitive Agreement with Agenus West LLC, and Agenus Inc., USA [collectively referred to as "Agenus"], to acquire, two U.S. based biologics manufacturing facilities of Agenus, one in Emeryville, CA and another in Berkeley, CA [collectively referred to as "Agenus Facilities"]. The transaction had been completed on January 15, 2026. The cost of acquisition is USD 75 Million as upfront consideration, subject to certain closing adjustments, and contingent payment of up to USD 50 Million over three years subject to achievement of certain revenue milestones. The results include the operations of Agenus Facilities effective from January 15, 2026, with provisional PPA figures. The PPA figures will be finalized within the measurement period, as provided by Ind AS 103.

[12] On May 13, 2026, Zydus Worldwide DMCC [ZWD], a wholly owned subsidiary, had signed a definitive agreement, through its wholly owned acquisition subsidiary Zara Merger Sub Inc. [Zara], with Assertio Holdings, Inc. [Assertio], to acquire all outstanding shares of Assertio for USD 23.50 per share in cash for consideration of approximately USD 166.4 Million on a fully-diluted basis, by cash tender offer. The transaction of the cash tender offer, by Zara for all the outstanding common stock of Assertio, has been completed on June 16, 2026. Subsequently, Zara was merged with and into Assertio, pursuant to which Assertio has become a wholly owned subsidiary of the Group. The results include the operations of Assertio effective from June 16, 2026, with provisional PPA figures. The PPA figures will be finalized within the measurement period, as provided by Ind AS 103.

[13] ZPUI, a wholly owned subsidiary, has reached in-principle agreement to resolve four class action antitrust lawsuits brought by Indirect Reseller Plaintiffs. The plaintiffs alleged that numerous pharmaceutical manufacturers, including ZPUI, engaged in anti-competitive behaviour. The settlement contains no admission of liability or wrongdoing by ZPUI. ZPUI remains committed to conducting its business in full compliance with all applicable laws. Resolving these matters allows ZPUI to focus on its mission and ongoing business operations. The parties are in the process of formalizing the agreement and expect final approval from the court later this year.

[14] ZWD, a wholly owned subsidiary of the Group, has entered into settlement agreement with Teva Pharmaceutical Industries Ltd. and Teva API Inc. [jointly referred to as Teva Parties] for ongoing litigation related to breach of obligation under Asset Purchase Agreement dated June 16, 2016 and breach of obligation under Letter of Intent dated May 24, 2016 for supply of Active Pharmaceuticals Ingredients. Pursuant to the settlement, the Teva Parties have paid a total amount of INR 1,468 Million [USD 15.5 Million] to ZWD.

[15] The Board of Directors at their meeting held on May 19, 2026, approved the proposal for buyback of equity shares, on proportionate basis, through tender offer route, amounting to INR 11,000 Million at a price not exceeding INR 1,150 per share [Buyback Price]. Subsequently, as per Regulation 5 [via] of the SEBI [Buy-back of Securities] Regulations, 2018, the Buyback Committee, at its meeting held on May 27, 2026 has approved increase in buyback price from INR 1,150 per share to INR 1,260 per share. Pursuant to buyback, the Parent has extinguished 8,730,158 equity shares [representing 0.87% of the total number of equity shares of the Parent] on June 18, 2026, in compliance with the applicable rules and regulations. Consequently, the paid up equity share capital has been reduced by INR 8 Million. The aggregate amount paid for the buy back is INR 11,063 Million, including related expenses.

[16] The figures of the quarter ended March 31, 2026 are balancing figures between audited figures in respect of the full financial year and year to date figures upto the third quarter of the said financial year.

[17] Figures of previous reporting periods/ year have been regrouped/ reclassified wherever necessary to correspond with the figures of the current reporting periods.

[18] The detailed standalone results are available on the Company's website: www.zyduslife.com, on the website of BSE [www.bseindia.com] and on the website of NSE [www.nseindia.com]. The summarised standalone financial results of the Company are as below:

	INR Million			
	Quarter ended			Year ended
	30/06/2026	31/03/2026	30/06/2025	31/03/2026
Particulars	(Unaudited)	(Unaudited) (Refer Note-16)	(Unaudited)	(Audited)
Revenue from operations	28,722	37,409	25,883	114,840
Profit before exceptional items and tax	4,557	22,178	4,749	45,488
Profit before Tax	4,557	21,110	4,749	43,819
Profit after Tax	3,396	17,220	3,847	35,598

For Identification Purposes Only
DELOITTE HASKINS & SELLS LLP
CHARTERED ACCOUNTANTS
MUMBAI

By Order of the Board,
For Zydus Lifesciences Limited,

Dr. Sharvil P. Patel
Managing Director
DIN: 00131995

Ahmedabad, August 11, 2026